Effect of Acetaminophen on relief of bone pain due to PEG G-CSF

comparison of the efficacy and complication of two medication regimen 'naproxen and loratadin’ with 'acetaminophen and loratadin' on relief of bone pain due to PEG G-csf in patients with solid tumors chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190514043586N1

Enrollment

200

Registered

2019-05-31

Start date

2019-06-05

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Pain Due to PEG G-CSF. Non-follicular lymphoma

Interventions

Intervention 1: Intervention group1:Tab Acetaminophene 500 mg orally every 6 hours +Tab Loratadine 10 mg orally daily, from Kimidarou manufacturer, duration of drug use is from pain onset to 48 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People with Solid Tumor or Lymphoma who receive PEG G-CSF due to neutropenia after chemotherapy

Exclusion criteria

Exclusion criteria: Bone matastasis PFS more than 2 Osteomalacia proven with laboratory tests CKD or ESRD Active Rheumatologic disease Uncontrolled Diabetes or Thyroid disease Patients receiving chemotherapy drugs that have bone pain are a high prevalence of 10% (TAXAN family, bisphosphonate ...) Pathologic fracture or fracture due to any reason Naproxen use contraindication Vitamin D level less than 20 Paget disease Hyperparathyroidism People who have had a score of over 6 in the bone pain score since the beginning of the project Liver disease History of Cardiac Arrhythmia Patient who have not compliance for completing pain questionnaire

Design outcomes

Primary

Measure	Time frame
Pain Score in Visual Analogue Scale(VAS) questionnaire. Timepoint: Day 0; One day after the end of first and third course of chemotherapy. Method of measurement: Visual Analogue Scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Amir Sheykholeslami

Shahid Beheshti University of Medical Sciences

amirsheikholeslami@gmail.com+98 21 7343 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026